Skip to main content
All lobbying clients

FERRING PHARMACEUTICALS, INC.

Lobbying client · New Jersey · filed 2025 to 2026

A privately-held biopharmaceutical company.

$2,900,000 Reported spend
37 Filings counted
5 Outside firms hired
13 Bills named

Spend is reported income plus in-house expenses across 37 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 6 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as FERRING PHARMACEUTICALS INC.

 Who filed for this client 6

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 13
  • H.R. 1878
    IVF Access and Affordability Act
    7 filings
  • H.R. 1670
    Family Building FEHB Fairness Act
    5 filings
  • H.R. 220
    Veterans Infertility Treatment Act of 2025
    5 filings
  • H.R. 4639
    Infertility Treatment Affordability Act of 2025
    5 filings
  • S. 797
    Family Building FEHB Fairness Act
    5 filings
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
    4 filings
  • H.R. 6797
    Bipartisan IVF for Military Families Act
    3 filings
  • H.R. 8119
    HOPE with Fertility Services Act
    3 filings
  • H.R. 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fisc…
    2 filings
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
    2 filings
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…
    1 filing
  • H.R. 1
    One Big Beautiful Bill Act
    1 filing
  • H.R. 7841
    Warrior Infertility Act
    1 filing
 Reported by year 2 years
  • 2026 $1,390,000 15 filings
  • 2025 $1,510,000 22 filings
 Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 8
  • HOUSE OF REPRESENTATIVES 24
  • SENATE 24
  • Commerce, Dept of (DOC) 8
  • Executive Office of the President (EOP) 7
  • Health & Human Services, Dept of (HHS) 7
  • U.S. Trade Representative (USTR) 6
  • White House Office 3
  • Bureau of Industry and Security (BIS) 1
 Recent filings 38 total
Q3 reportNo activity
HILLSTAFFER, LLC
3rd Quarter 2026 (July 1 - Sep 30) · posted Oct 20, 2026
View →
Q3 report
FERRING PHARMACEUTICALS, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $260,000 expenses · posted Oct 19, 2026
View →
Q3 report
BAKER & HOSTETLER LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 19, 2026
View →
Q3 report
BROWNSTEIN HYATT FARBER SCHRECK, LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 17, 2026
View →
Q3 report
BALLARD PARTNERS
3rd Quarter 2026 (July 1 - Sep 30) · $110,000 income · posted Oct 16, 2026
View →
Q2 reportNo activity
HILLSTAFFER, LLC
2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 28, 2026
View →
Q2 report
BROWNSTEIN HYATT FARBER SCHRECK, LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
FERRING PHARMACEUTICALS, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $250,000 expenses · posted Jul 18, 2026
View →
Q2 report
BAKER & HOSTETLER LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 18, 2026
View →
Q2 report
BALLARD PARTNERS
2nd Quarter 2026 (Apr 1 - June 30) · $110,000 income · posted Jul 14, 2026
View →
Q1 reportNo activity
HILLSTAFFER, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 21, 2026
View →
Q4 termination
TODD STRATEGY GROUP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
BAKER & HOSTETLER LLP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 19, 2026
View →
Q1 report
BROWNSTEIN HYATT FARBER SCHRECK, LLP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 18, 2026
View →
Q1 report
FERRING PHARMACEUTICALS, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $220,000 expenses · posted Apr 18, 2026
View →
Q1 report
BALLARD PARTNERS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $110,000 income · posted Apr 15, 2026
View →
Q4 reportNo activity
HILLSTAFFER, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 24, 2026
View →
Q4 report
TODD STRATEGY GROUP Amended
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
BROWNSTEIN HYATT FARBER SCHRECK, LLP
4th Quarter 2025 (Oct 1 - Dec 31) · House · $80,000 income · posted Jan 20, 2026
View →
Q4 report
BAKER & HOSTETLER LLP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 17, 2026
View →

Showing the 20 most recent of 38 filings. Search the explorer for "FERRING PHARMACEUTICALS, INC.".

 Foreign entities disclosed 1
  • FERRING HOLDING SA Switzerland named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem